FX Medicine

Home of integrative and complementary medicine

Clinician's Perspective | Cholesterol Tests: Sending the Wrong Message

robert_buist's picture

There’s a small, but significant revolution going on in our understanding of heart disease risk factor markers.

Most practitioners have a basic awareness of the general comings and goings of cholesterol in the body; that most of the body’s cholesterol is carried through the bloodstream in the form of lipoproteins known as LDL (low-density lipoproteins) and HDL (high-density lipoproteins) and that the LDL delivers cholesterol to relevant tissues while HDL removes it from the arteries and transports it to the liver. 

Keeping it simple for the public, LDL was generally referred to as the “bad” guy that clogs our arteries while HDL was the “good” guy because it removes cholesterol from the arteries. In the light of recent research it’s time to revise this simplistic view. 

We now know that LDL can be fractionated into 7 different types (see diagram below). Two of these are good for you (LDL 1 and 2) and deliver the much needed cholesterol throughout the body. The other five; (LDL 3,4,5,6,7) are dangerous because they have been damaged in some way due to a poor diet and metabolic “wear and tear”.  The body wants to get rid of these types, rapidly shunting them into foam cells which form the basis of plaque in the arteries.  These foam cells are strongly causal in the development of atherosclerosis.

The non-harmful, undamaged LDL 1 and 2 are described as large and fluffy (referred to as pattern A) while the damaged, small denser LDLs (3-7) are called pattern B.  People with a predominance of pattern B are more likely to have a heart attack.

The real issue with both LDL and HDL is the type of protein that wraps around each lipid package and interacts with the vessel wall. In the case of LDL the protein is called ApoB and for HDL it is ApoA1.

There is only one ApoB associated with each LDL package, so if a certain amount of the LDL takes the form of “large and fluffy” this obviously reduces the possible number of “small and dense” particles.

This provides a straightforward way to assess the ratio between LDLs - large and harmless vs small and dangerous.  It’s either one or the other.  The higher the quantity of ApoB detected in the blood, the higher the likelihood of small dense particles being present and thus the greater is the risk of damage to the blood vessels. This is because the ApoB amino acids can be, and probably have been, modified by oxidation or glycation, involving many agents which lead to inflammation and plaque formation.

So even though the LDL cholesterol measurement is low, there may still be a problem with large amounts of dangerous ApoB if these LDLs are small and dense.  

It’s usually assumed that HDLs are functional and efficacious in removing cholesterol from the arteries. However they too can be damaged and non-functional. In a similar picture to the ApoB mechanism there is only one ApoA-1 protein per HDL package. This protein can also be modified by oxidation or glycation causing a reduced particle size, increased density and decreased functional HDL, although it is not as vulnerable as the ApoB.

It should also be noted that ApoA-1 has many other functions. It is involved in anti-inflammatory, antioxidation, anti-infectious activity and anti-thrombotic functions. It can also initiate the endothelial production of nitric oxide that is vital for vasodilation and can regulate glucose/insulin homeostasis.

All this means that a high ApoB:ApoA-1 ratio can now tell us a lot about heart disease and the risk of heart attack. The higher the number, the higher the risk. No need to worry about units anymore as it is just a ratio.

So our strategy should aim to decrease the number of ApoB carriers (representing the small atherosclerotic LDLs) and increase the ApoA-1 carriers representing the effectiveness of reverse cholesterol transport. 

Specialized pathology labs can now fractionate LDLs into their 7 component parts and also measure ApoB and ApoA-1. This gives much more information about a person’s risk of heart disease and should now be added to the more standard measurements of total cholesterol, LDL, HDL and triglycerides.

Case Study

Here’s an example of a patient with a previous heart attack who had three stents inserted in the LAD and circumflex arteries, and who was on Plavix 75mg, aspirin 100mg and Pravastatin 40mg daily. He undertook a change in diet and nutrition supplements that reduced oxidation, inflammation and glycation. 

This involved eating whole seasonal foods, high in vegetables, fruit, legumes, fibre, cold water fish, meats and eggs, removing all sugar and using only cold pressed olive oil. He also took the following nutrition supplements daily after the stents were placed:

Bergamot 500mg, Glutathione 250mg, Tocotrienol/tocopherol mix 250mg, CoEnzyme Q10 300mg, Resveratrol 250mg, Vitamin D 5,000iu, Omega-3 oils 2g, 12 Strain probiotic 60 billion CFU, Magnesium glycinate 300mg and Theracumin 250mg.

Results

You can see that the LDL dropped from 6.2 to 3.0 mmol/l within 6 months of starting Pravastatin/Bergamot and changing the diet but the interesting question from our discussion so far is how much of this LDL is made up of harmless LDL 1 and 2 verses other LDLs 3,4,5,6,7?. The answer is that the light fluffy LDL 1 and 2 increased from 1.58 and 1.32 respectively to the higher amounts of 1.7 and 1.5. This is good. At the same time the small dense atherosclerotic varieties LDL 3,4,5,6,7 were reduced. This trend is going in the right direction under the influence of the antioxidant/anti-inflammatory supplements. 

In addition we note a welcomed decrease in ApoB from 1.58 to 0.92 together with a concomitant increase in ApoA-1 from 1.50 to 1.69.

So the initial high risk ApoB:ApoA-1 ratio of 1.05 has been reduced to the nearly ideal ratio of 0.54. This is meaningful. It tells us that a potential atherosclerotic situation where the lipoproteins have been damaged has now reverted to a less harmful one in which more non-oxidised and non glycated lipoproteins are available to deliver the necessary cholesterol to cells and remove excess cholesterol according to normal body dynamics.

By being able to measure the lipoprotein sub-fractions together with the ApoB:ApoA-1 ratio we now have a real handle on the type of lipoproteins present, their effectiveness and whether they have been damaged or not. We now have much better tools to monitor the situation.

References

  1. Walldius G. The apoB/apoA-I Ratio is a strong predictor of cardiovascular risk In: Frank S, Kostner G (Eds). Lipoproteins - Role in health and diseases. InTech, 2012. [Link]
     
  2. Vaverkova H. LDL-C or apoB as the best target for reducing coronary heart disease. Clin Lipidology 2011;6(1):35-48. [Full Text
     
  3. Lamarche B, Lemieux I and Despres JP. The small, dense LDL phenotype and the risk of coronary heart disease: epidemiology, patho-physiology and therapeutic aspects. Diabetes Metab 1999;25(3):199-211. [Abstract

In his book "Love Your Cholesterol", Dr Robert Buist re-examines the universal phobia about high cholesterol and saturated fat. 

He shines a spotlight on our changing food supply which now favors an increase in consumption of polyunsaturated seed oils and refined carbohydrates/sugars against a scarcity of anti-inflammatory compounds, antioxidants and other important phytonutrients

 


DISCLAIMER: 

The information provided on FX Medicine is for educational and informational purposes only. The information provided on this site is not, nor is it intended to be, a substitute for professional advice or care. Please seek the advice of a qualified health care professional in the event something you have read here raises questions or concerns regarding your health. 

Share Article: 

SIGN UP TO OUR FREE eNEWS

robert_buist's picture
Robert Buist PhD
Dr Robert Buist, Australia’s leading nutritionist, has more than 20 years of experience in the health industry from research to clinical practice, teaching and product formulations. Dr Buist’s research has covered such areas as glucose metabolism and the development of new drugs for the treatment of asthma and heart disease. Dr Buist lectures extensively around Australia and overseas to doctors, pharmacists and other health professionals. He is a regular nutrition expert on radio and television and was Editor-in-Chief of the international Clinical Nutrition Review for 22 years. He directs a private nutritional medicine clinic in Sydney and has produced over 20 research papers and three best-selling nutrition books: Food Intolerance, Food Chemical Sensitivity and The Cholesterol Myth.